Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139992 · ClinicalTrials.gov registry record
COVID-19 Vaccine Response in Sickle Cell Disease
A clinical trial, sponsored by ASH Research Collaborative.
- Completed
- Registry status
- 59
- Enrollment target
NCT05139992: Completed study, sponsored by ASH Research Collaborative.
NCT05139992 is a clinical trial that has completed, run by ASH Research Collaborative. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05139992 has completed, sponsored by ASH Research Collaborative.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.
Primary Outcome
IgG ELISA based antibody titer to SARS-CoV-2 spike RBD antigen
Interventions
- BIOLOGICAL COVID-19 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT05139992 record still lists
NCT05139992 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 Vaccine is the first listed.
NCT05139992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05139992 about?
NCT05139992 is a clinical study titled "COVID-19 Vaccine Response in Sickle Cell Disease". The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.
What is the current status of trial NCT05139992?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2021-12-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05139992?
The interventions under investigation include: COVID-19 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05139992?
This trial is sponsored by ASH Research Collaborative, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI